December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.84 +1.36 (+6.67%)
Streaming Delayed Price Updated: 1:39 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
35 36 Next >
News headline image
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials. 
Via MarketBeat
News headline image
How Is The Market Feeling About Sarepta Therapeutics? ↗
 
Via Benzinga
News headline image
A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today ↗
 
Via Benzinga
News headline image
2 Biotech Stocks to Buy Hand Over Fist in August ↗
Both of these biotechs are highly innovative companies. 
Via The Motley Fool
News headline image
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗
These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers. 
Via Benzinga
News headline image
Smart Money Is Betting Big In SRPT Options ↗
 
Via Benzinga
News headline image
NASDAQ:SRPT may be ready to breakout. ↗
NASDAQ:SRPT may be ready to breakout. 
Via Chartmill
News headline image
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics ↗
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments. 
Via Investor's Business Daily
News headline image
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
7 Biotech Stocks to Buy for Their Game-Changing Potential ↗
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
News headline image
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript ↗
SRPT earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
26 Analysts Have This To Say About Sarepta Therapeutics ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
3 Genomics Stocks That May Transform Personalized Medicine ↗
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. 
Via InvestorPlace
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts ↗
 
Via Benzinga
News headline image
Looking At Sarepta Therapeutics's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know. ↗
The CEO of Cassava Sciences is stepping down, effective immediately. Here's what this means for troubled SAVA stock. 
Via InvestorPlace
News headline image
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' ↗
Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde. 
Via Benzinga
News headline image
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
From Cassava Sciences, Inc.
Via GlobeNewswire
News headline image
After a Big Win, Is Sarepta Therapeutics Stock a Buy? ↗
One key issue remains unresolved, and it could be a significant one. 
Via The Motley Fool
News headline image
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News? ↗
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead. 
Via The Motley Fool
News headline image
1 Soaring Growth Stock to Buy and Hold for 10 Years ↗
Let's look beyond the biotech's performance this year. 
Via The Motley Fool
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It. ↗
One company's negative results can increase scrutiny of another's work. 
Via The Motley Fool
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.